Literature DB >> 28844618

Impact of pain and pain subtypes on the quality of life of patients with Parkinson's disease.

Seong-Min Choi1, Byeong C Kim2, Hyun-Jung Jung3, Geum-Jin Yoon3, Kyung Wook Kang3, Kang-Ho Choi4, Joon-Tae Kim3, Seung-Han Lee3, Man-Seok Park3, Myeong-Kyu Kim3, Ki-Hyun Cho3.   

Abstract

Pain is a frequent and troublesome non-motor symptom of Parkinson's disease (PD) and has a negative impact on quality of life (QoL). The aim of this study was to investigate the relative impact of pain or a specific pain subtype on the QoL of patients with PD. We included 161 patients with PD. Pain was assessed using the patients' descriptions, a structured interview, and a detailed neurological examination. QoL was assessed using the 39-item Parkinson's Disease Questionnaire (PDQ-39). One hundred and twenty (74.5%) patients with PD had chronic pain. Musculoskeletal pain was the most prevalent type, followed by radicular/neuropathic, dystonic, and central pain. PD patients with pain, regardless of the pain subtype, had a worse PDQ-39 score than those without pain. Multivariate regression analysis after adjusting for disease-related factors and motor characteristics showed that younger PD onset age and the high scores of part II of Unified Parkinson's Disease Rating Scale, Beck Depression Inventory, and Visual Analogue Scale were significant predictors of the poor PDQ-39 score. Pain along with depression, poor activities of daily living, and younger age of PD symptom onset are associated with poor QoL. All subtypes of pain affect QoL of patients with PD. Pain should be considered during the management of patients with PD.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Non-motor symptoms; Pain; Parkinson’s disease; Quality of life

Mesh:

Year:  2017        PMID: 28844618     DOI: 10.1016/j.jocn.2017.08.002

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  6 in total

1.  Relationship of Nocturnal Sleep Dysfunction and Pain Subtypes in Parkinson's Disease.

Authors:  Pablo Martinez-Martin; Alexandra M Rizos; John B Wetmore; Angelo Antonini; Per Odin; Suvankar Pal; Rani Sophia; Camille Carroll; Davide Martino; Cristian Falup-Pecurariu; Belinda Kessel; Thomasin Andrews; Dominic Paviour; Claudia Trenkwalder; Kallol Ray Chaudhuri
Journal:  Mov Disord Clin Pract       Date:  2018-11-08

2.  Dynamic Functional Connectivity and Symptoms of Parkinson's Disease: A Resting-State fMRI Study.

Authors:  Gwenda Engels; Annemarie Vlaar; Brónagh McCoy; Erik Scherder; Linda Douw
Journal:  Front Aging Neurosci       Date:  2018-11-23       Impact factor: 5.750

3.  Evolution of Quality of Life in Persons with Parkinson's Disease: A Prospective Cohort Study.

Authors:  Eduardo Candel-Parra; María Pilar Córcoles-Jiménez; Victoria Delicado-Useros; Antonio Hernández-Martínez; Milagros Molina-Alarcón
Journal:  J Clin Med       Date:  2021-04-22       Impact factor: 4.241

4.  Evaluating the effects of dance on motor outcomes, non-motor outcomes, and quality of life in people living with Parkinson's: a feasibility study.

Authors:  Anna M Carapellotti; Matthew Rodger; Michail Doumas
Journal:  Pilot Feasibility Stud       Date:  2022-02-09

Review 5.  Chronic Pain Treatment Strategies in Parkinson's Disease.

Authors:  Amber Edinoff; Niro Sathivadivel; Timothy McBride; Allyson Parker; Chikezie Okeagu; Alan D Kaye; Adam M Kaye; Jessica S Kaye; Rachel J Kaye; Meeta M Sheth; Omar Viswanath; Ivan Urits
Journal:  Neurol Int       Date:  2020-11-18

6.  Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial.

Authors:  K Ray Chaudhuri; Per Odin; Joaquim J Ferreira; Angelo Antonini; Olivier Rascol; Mónica M Kurtis; Alexander Storch; Kirsty Bannister; Patrício Soares-da-Silva; Raquel Costa; Diogo Magalhães; José Francisco Rocha
Journal:  BMC Neurol       Date:  2022-03-12       Impact factor: 2.474

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.